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Summary
The notion that the adult heart of mammals including humans contain a small population of 
resident cardiac progenitor/stem cells (CSCs) have questioned the traditional paradigm of the 
myocardium as a post-mitotic terminally differentiated tissue. These cells, however, are rela-
tively scarce and unable to be recruited in large number at the site of tissue damage. This has 
sparkled novel interest in the identification of molecules capable of stimulating the regenera-
tive potentials of CSCs in their microenvironment. In this context, the peptide hormone relaxin 
(RLX), recently validated as a cardiovascular hormone, deserves a key place. This article sum-
marizes the most recent findings of our group on the ability of RLX to modulate growth and 
differentiation of mouse neonatal cardiomyocytes, suggesting that this hormone, for which the 
heart is both a source and target organ, may participate in the endogenous mechanisms of myo-
cardial repair/regeneration. Moreover, we have recently observed that RLX, by a Notch-1-medi-
ated mechanism, inhibits cardiac myofibroblast differentiation and function, suggesting that the 
known anti-fibrotic effects of RLX may be part of a complex network of actions whereby this 
hormone facilitates cardiac stem cell growth and improves myocardial regeneration. 
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Starting from the end of 20th century, the discoveries on the regenerative potential 
of stem cells and the possibility to use stem cell therapy as a treatment of heart fail-
ure has represented a field of intensive experimental and clinical research (Leri et al. 
2008). Moreover, the paradigm that the adult heart represent a terminally differenti-
ated organ has been recently challenged by the identification of resident cardiac stem 
cells (CSCs) which could be recruited to cardiac repair. Anyhow, even if few question 
are definitively addressed in the field of cardiac repair, it seems well accepted that 
a functionally significant myocardial regeneration, especially after massive muscle 
tissue loss as occurs upon myocardial infarction, cannot be achieved by either resi-
dent or transplanted stem cells (Formigli et al. 2010). Therefore, increasing the cur-
rent knowledge on the factors and their mechanisms of action which may enhance 
the regenerative ability of cardiac stem cells represents a major research objective. In 
this scenario, relaxin (RLX) deserves a key place. In fact, the heart is both a source 
and specific target organ for RLX (Nistri et al 2007). In the last years, evidence has 
been offered that RLX, administered exogenously or secreted locally by genetically 
engineered stem cells grafted into the infarcted heart in experimental animals, reduc-
es ischemic myocardial injury and dysfunction (Nistri et al 2007; Formigli et al. 2010). 
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Moreover, RLX knock-out mice are prone to develop cardiac fibrosis, a phenotype 
that can be reversed by exogenous RLX (Du et al. 2003). More recently, using primary 
cultures of mouse myocardial precursors, RLX was shown to up-regulate the co-ordi-
nate expression of cardiogenic transcription factors (GATA-4 and Nkx2-5) and related 
structural myocardial genes (connexin 43, troponin T and HCN4 ion channel), there-
by promoting the development of morphological and electrophysiological features of 
mature cardiomyocytes (Nistri et al. 2012). 
It is well known that the three-dimensional arrangement of the developing heart – 
like any other organ - depends on the interaction between myocardial precursor and 
stromal cells of mesenchymal origin. In particular, mesenchymal stromal cells (MSCs) 
have the unique ability to create a network which moulds the shape of the organ, in 
which myocardial precursors can settle, proliferate and differentiate (Bani et al. 2010). 
Recent in vitro evidence has been provided that such cardiomyocyte-MSC interactions 
are dependent on juxtacrine signals operated by the interaction between the plasma 
Figure 1. Schematic diagram of the effects of relaxin (RLX) on the stem cell populations in the heart. CSC, 
cardiac stem cell; MSC, mesenchymal stromal cell; CM, cardiomyocyte; RXFP1, relaxin family receptor 1; Cx43, 
connexin 43; cTnT, cardiac-specific troponin T. The cross-banded cytoplasmic structures in the developing 
cardiomyocyte are leptomeres, required for correct myofibril assembly.
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membrane receptor Notch-1 and its ligand Jagged-1, which are crucial to promote 
cardiomyocyte growth (Sassoli et al. 2012). Based on this background, we have then 
demonstrated that RLX can enhance Notch-1 in cultured MSCs, thereby interfering 
with TGF-b signalling, the major pro-fibrotic cytokine, and inhibiting the transforma-
tion of MSCs into collagen-producing myofibroblasts (unpublished data). These find-
ings fit well with the known anti-fibrotic effects of RLX (Samuel et al. 2007) and sug-
gest that, by similar mechanisms, RLX could improve the whole process of post-in-
farction cardiac remodelling, shifting it from spontaneous reparative scarring towards 
a myocardial regenerative pattern reminiscent of the embryonic heart development.
Taken together, the above notions suggest that RLX can be an endogenous reg-
ulator of cardiac morphogenesis during pre-natal life, acting on both myocardial 
and stromal precursor cells (Figure 1). Going a step further, RLX may be regarded 
as a novel cardiotropic drug useful to enhance the repair and – hopefully – promote 
regeneration of the diseased heart during adult life.
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